312 results
Name Type Target Compound Name Phase
Collaboration: University of Milano–Bicocca; The National Center of Healthcare Research and Pharmacoepidemiology; Fondazione IRCCS Istituto Nazionale dei Tumori

We carried out a population-based case–control study to test the use of angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in patients with COVID-19.

Research (ACE2 Receptor)
Moleculin Biotech

WP1122 has the potential to solve 2-DG’s problem by creating a prodrug of 2-DG that reaches much higher tissue/organ concentrations than 2-DG alone.

New Therapies (Small Molecule) 2- DG WP1122 Pre-Clinical
Collaboration: SOM Biotech; Ewha Womans University

SOM Biotech has applied its artificial intelligence-based screening technology (SOMAIPRO) to identify inhibitors of the 3CL proteases of SARS-CoV-2, SARS-CoV and MERS-CoV viruses as potential candidates to treat COVID-19

New Therapies (Small Molecule) 3C-like proteases; RpsE Eravacycline, Prexasertib Pre-Clinical

Eutilex has launched a COVID-19 treatment using immune antibody. They plan to develop 4-1bb agonist monoclonal antibody

New Therapies (Antibody-based) 4-1BB (CD137) Unnamed Pre-Clinical
Agastiya Biotech

AB001 acts on ACE-2 to inhibit the entry of the virus into the cell and also works on NSP15 to prevent its replication

Research (ACE2 Receptor) ACE2 receptor AB001 Pre-Clinical
Collaboration: University of British Colombia, Apeiron Biologics, Karolinska Institute, National Veterinary Institute of Sweden, Institute for Bioengineering of Catalonia (IBEC), Institute of Molecular Biotechnology of the Austrian Academy of Sciences, STEMCELL Technologies Inc., Center for Applied Medical Research (CIMA), University of Toronto, Catalan Institution for Research and Advanced Studies (ICREA), Centro de Investigación Biomédica en Red en Bioingeniería

Inhibition of SARS-CoV-2 infection of human organoids using recombinant human ACE2

Research (ACE2 Receptor) ACE2 receptor APN01 Phase II
Assistance Publique - Hôpitaux de Paris

Protective Role of Inhaled Steroids for Covid-19 Infection

New Therapies (Small Molecule) ADRB2 Symbicort Rapihaler Phase III
Radboud University

Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease. Currently available AT1R blockers (ARBs) such as valsartan, have the potential to block this pathological process mediated by angiotensin II.

New Therapies (Small Molecule) AT1 receptor (AGTR1) Diovan valsartan Phase IV
Collaboration: National Institute of Allergy and Infectious Diseases; Centers for Disease Control and Prevention; Princeton University; University of California, Los Angeles;

SARS-CoV-2 and SARS-CoV-1 stability in aerosols and on various surfaces

Research (Epidemiology) Aerosol and surface stability N/A Pre-Clinical
Applied Therapeutics

Clinical trial of lung inflammation and cardiomyopathy drug

Research (Drug Repurposing) Aldose reductase AT-001 Expanded access
Massachusetts Institute of Technology (MIT)

Generation of 23-amino acid peptide homologous to the ACE2 receptor alpha helix

New Therapies (Protein-based) Angiostein Converting Enzyme 2 (ACE2) receptor N/A Research
University of Pennsylvannia

Effects of genetic variants of human ACE2 protein on SARS-CoV-2 spike protein binding

Vaccine Development Angiostein Converting Enzyme 2 (ACE2) receptor N/A Research
Impact BioMedical

Impact’s parent company Singapore eDevelopment said March 17 that Impact and scientific research partner GRDG Sciences conducted molecular docking studies using advanced computational models showing that its Linebacker and Equivir compounds successfully inhibited infection by SARS-CoV-2. The compounds will undergo testing after they were shown to block 3 integral viral mechanisms for SARS-CoV-2 replication and infection: the viral spike interaction point, helicase, and protease.

Vaccine (Protein Subunit) Angiostein Converting Enzyme 2 (ACE2) receptor Linebacker and Equivir Pre-Clinical
Collaboration: Goethe University; University Hospital Frankfurt; German Centre for Infection Research (DZIF); Frankfurt Cancer Institute; Cardio-Pulmonary Institute

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

Research (ACE2 Receptor) Angiostein Converting Enzyme 2 (ACE2) receptor N/A Research
La Jolla Pharmaceutical

La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Münster in Germany

New Therapies (Small Molecule) Angiotensin II type 1 (AT1) receptor (AGTR1) Giapreza angiotensin II Expanded access
University of California, San Franscico

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

New Therapies (Small Molecule) Angiotensin-converting enzyme (ACE) Captopril Pre-Clinical

Apabetalone prevents specialized proteins – called bromodomain and extraterminal domain (BET) proteins – from activating the expression of disease-associated and other genes, potentially disrupting SARS-CoV-2 reproduction while also limiting the entry of the virus into human cells.

New Therapies (Small Molecule) BET bromodomain proteins Apabetalone Pre-Clinical
Collaboration: Grifols and U.S. Department of Health and Human Services

Development of treatments using plamsa from Covid 19 patients

New Therapies (Antibody-based) Blood plasma Anti-SARS-CoV-2 hyperimmune globulin Pre-Clinical

Preliminary human trial of CCR5 antagonist leronlimab

New Therapies (Antibody-based) CCR5 PRO 140 Phase II
University of California, Davis; Center for Immunology and Infectious Disease

UC Davis researchers create biobank for biospecimens from patients exposed to SARS-CoV-2

New Therapies (Antibody-based) COVID-19 patient biosamples N/A Pre-Clinical
Scripps Research

Looking for COVID-19 convalescing patients to donate blood for antibody characterization

New Therapies (Antibody-based) COVID-19 patient blood samples Unnamed Pre-Clinical
Swedish University of Agricultural Sciences

Genetic changes with time in canine respiratory coronavirus in Sweden

Research (Non-Human) Canine respiratory coronavirus N/A Pre-Clinical
IRCCS San Raffaele

  • Use of Defibrotide to Reduce Progression of Acute Respiratory Failure Rate in Patients With COVID-19 Pneumonia
New Therapies (Oligonucleotide) Cathepsin G (CTSG) Defibrotide Phase II

Eculizumab (Soliris) in Covid-19 Infected Patients (SOLID-C19)

New Therapies (Antibody-based) Complement 5 (C5) Soliris eculizumab Expanded access

Alexion Announces Plans to Initiate Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19

New Therapies (Antibody-based) Complement 5 (C5) Ultomiris ravulizumab-cwvz IND